Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
EASL International Liver Foundation, Geneva, Switzerland.
Hepatology. 2023 Sep 1;78(3):911-928. doi: 10.1097/HEP.0000000000000361. Epub 2023 Apr 18.
Fatty liver disease is highly prevalent, resulting in overarching wellbeing and economic costs. Addressing it requires comprehensive and coordinated multisectoral action. We developed a fatty liver disease Sustainable Development Goal (SDG) country score to provide insights into country-level preparedness to address fatty liver disease through a whole-of-society lens.
We developed 2 fatty liver disease-SDG score sets. The first included 6 indicators (child wasting, child overweight, noncommunicable disease mortality, a universal health coverage service coverage index, health worker density, and education attainment), covering 195 countries and territories between 1990 and 2017. The second included the aforementioned indicators plus an urban green space indicator, covering 60 countries and territories for which 2017 data were available. To develop the fatty liver disease-SDG score, indicators were categorized as "positive" or "negative" and scaled from 0 to 100. Higher scores indicate better preparedness levels. Fatty liver disease-SDG scores varied between countries and territories (n = 195), from 14.6 (95% uncertainty interval: 8.9 to 19.4) in Niger to 93.5 (91.6 to 95.3) in Japan; 18 countries and territories scored > 85. Regionally, the high-income super-region had the highest score at 88.8 (87.3 to 90.1) in 2017, whereas south Asia had the lowest score at 44.1 (42.4 to 45.8). Between 1990 and 2017, the fatty liver disease-SDG score increased in all super-regions, with the greatest increase in south Asia, but decreased in 8 countries and territories.
The fatty liver disease-SDG score provides a strategic advocacy tool at the national and global levels for the liver health field and noncommunicable disease advocates, highlighting the multisectoral collaborations needed to address fatty liver disease, and noncommunicable diseases overall.
脂肪肝疾病的发病率很高，给人们的整体健康和经济带来了巨大的负担。解决这个问题需要全面协调的多部门行动。我们开发了脂肪肝疾病可持续发展目标（SDG）国家评分，以通过全社会的视角来洞察各国在解决脂肪肝疾病方面的准备情况。
我们开发了 2 种脂肪肝疾病-SDG 评分系统。第一种包括 6 项指标（儿童消瘦、儿童超重、非传染性疾病死亡率、全民健康覆盖服务覆盖指数、卫生工作者密度和教育程度），涵盖了 195 个国家和地区的数据，时间跨度为 1990 年至 2017 年。第二种包括上述指标加上城市绿地指标，涵盖了 60 个国家和地区的 2017 年数据。为了开发脂肪肝疾病-SDG 评分，我们将指标分为“阳性”或“阴性”，并将其从 0 到 100 进行评分。分数越高表示准备水平越高。脂肪肝疾病-SDG 评分在各国和地区之间存在差异（n=195），从尼日尔的 14.6（95%置信区间：8.9 至 19.4）到日本的 93.5（91.6 至 95.3）；有 18 个国家和地区的评分高于 85。在区域层面上，高收入超级区域在 2017 年的得分最高，为 88.8（87.3 至 90.1），而南亚的得分最低，为 44.1（42.4 至 45.8）。1990 年至 2017 年间，所有超级区域的脂肪肝疾病-SDG 评分都有所增加，其中南亚的增幅最大，但有 8 个国家和地区的评分有所下降。
脂肪肝疾病-SDG 评分提供了一个在国家和全球层面上用于肝脏健康领域和非传染性疾病倡导者的战略宣传工具，突出了应对脂肪肝疾病和整体非传染性疾病所需的多部门合作。
